multiple myeloma

Showing 15 posts of 68 posts found.


FDA grants ODD to NXC-201 as multiple myeloma treatment

August 24, 2023
Medical Communications FDA, Nexcella, ODD, Oncology, multiple myeloma

Nexcella has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to NXC-201 for …


FDA approves Talvey for the treatment of heavily pretreated multiple myeloma

August 11, 2023
Medical Communications FDA, J&J, Janssen, Oncology, Talvey, multiple myeloma

The Janssen Pharmaceutical companies of Johnson & Johnson has announced that the US Food and Drug Administration (FDA) has granted …

Innate Pharma doses first patient in relapsed/refractory multiple myeloma trial

July 11, 2023
Research and Development Innate Pharma, Oncology, Sanofi, clinical trial, multiple myeloma

Innate Pharma has announced that the first patient has been dosed in its Sanofi-sponsored phase 1/2 clinical trial, which aims …


Janssen submits MAA to EMA for novel CAR-T cell therapy

May 5, 2021
Research and Development EMA, EU, Janssen, multiple myeloma

Janssen have submitted a Marketing Authorisation Application (MAA) to the EMA seeking approval of cilta-cel, an investigational B cell maturation …

New Sanofi Sarclisa treatment for multiple myeloma approved by FDA

April 1, 2021
FDA, FDA Approval, Sanofi, Sarclisa, multiple myeloma

Sanofi’s Sarclisa drug has been approved by the FDA in combination with carfilzomib and dexamethasone (Kd) for the treatment of …


NICE approves Sanofi’s Sarclisa combo for relapsed/refractory multiple myeloma

October 16, 2020
Medical Communications, Sales and Marketing NICE, Sanofi, Sarclisa, multiple myeloma

Sanofi’s Sarclisa (isatuximab) has secured a recommendation from NICE for routine use on the NHS in England and Wales as …


FDA committee backs GSK’s belantamab mafodotin in relapsed or refractory multiple myeloma

July 15, 2020
Research and Development, Sales and Marketing Cancer, FDA, GSK, multiple myeloma, pharma

The FDA’s Oncologic Drugs Advisory Committee (ODAC) has moved to recommend the use of GlaxoSmithKline’s belantamab mafodotin, or GSK2857916 as …


100% of multiple myeloma patients respond to Janssen’s investigational CAR T therapy, data shows

May 14, 2020
Research and Development CAR T, CAR-T, Janssen, multiple myeloma, pharma

Janssen has revealed new Phase1b/2 findings of the efficacy of its investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell …


Takeda’s Ninlaro combo fails to hit main goal in newly diagnosed, transplant ineligible multiple myeloma

March 11, 2020
Research and Development, Sales and Marketing Ninlaro, Takeda, multiple myeloma, pharma

Takeda has unveiled new Phase 3 data for its oral proteasome inhibitor Ninlaro (ixazomib) in the treatment of newly diagnosed …

Sanofi scores FDA approval for Sarclisa combo in relapsed, refractory multiple myeloma

March 3, 2020
Manufacturing and Production, Sales and Marketing Cancer, Sanofi, Sarclisa, multiple myeloma, pharma

Sanofi’s monoclonal antibody and CD-38 inhibitor Sarclisa (isatuximab-irfc) has been awarded marketing authorisation from the FDA in the treatment of …


FDA fast-tracks GSK’s multiple myeloma drug after priority review

January 22, 2020
Research and Development BCMA, FDA, GSK, Phase 2 Trials, Phase Trials, multiple myeloma, myeloma

The FDA has fast tracked GlaxoSmithKline (GSK) antibody drug conjugate (ADC) belantamab mafodotin, for the treatment of patients with refractory …


Myeloma UK reveals new Director of Research appointment

November 14, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Myleoma UK, appointment, multiple myeloma, pharma

UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, who in her new role …

Takeda’s Ninlaro shows progression-free survival benefit in multiple myeloma

November 8, 2019
Medical Communications, Research and Development Ninlaro, Takeda, multiple myeloma, pharma

Takeda has revealed strong new findings for Ninlaro (ixazomib), confirming that the therapy met its primary endpoint as a first-line …


Amgen’s Kyprolis + Darzalex combo shows progression-free survival benefit in multiple myeloma

September 16, 2019
Research and Development, Sales and Marketing Amgen, Kyrpolis, darzalex, multiple myeloma, pharma

Amgen has revealed new Phase 3 data for the combination of Kyprolis (carfilzomib) and Darzalex (daratumumab) in addition to the …


FDA approves multiple myeloma therapy Xpovio despite safety concerns

July 4, 2019
Sales and Marketing FDA, Karyopharm, Xpovio, multiple myeloma, pharma

The FDA has made the controversial decision to approve the nuclear export inhibitor Xpovio (selinexor) from Karyopharm Therapeutics, in combination …

Latest content